Stay updated on T-DXd in HER2 Expressing Tumors Clinical Trial
Sign up to get notified when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.

Latest updates to the T-DXd in HER2 Expressing Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedUpdated operating-status messaging and versioning: adds a funding-status notice and current open status, replaces the old Last Update/Revision labels with new wording, and marks the revision as v3.2.0 while removing v3.1.0.SummaryDifference2%

- Check31 days agoChange DetectedUpdates reflect a transition from v3.0.2 with August dates to v3.1.0 in September, with new status markers and contact info; overall meaning: the page is refreshed with current status and updated revision/version, while older August details are removed.SummaryDifference0.6%

- Check46 days agoChange DetectedUpdated the page from revision v3.0.1 to v3.0.2 and removed the 'Back to Top' link; overall, a minor update with no changes to pricing, stock, or time-based data.SummaryDifference0.1%

- Check53 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check60 days agoChange DetectedThe web page has been updated with new facility names and locations, including specific addresses in various countries, and a new publication related to Trastuzumab Deruxtecan. Additionally, the last update date has been changed to August 2025.SummaryDifference14%

- Check74 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%

Stay in the know with updates to T-DXd in HER2 Expressing Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.